Biogen Idec Reveals SEC Probe

Biogen Idec announced a formal investigation by the Securities and Exchange Commission into whether the company violated securities laws during its withdrawal of multiple sclerosis drug Tysabri in February. In its SEC filing for the first quarter released Friday, the company said it received a formal order of investigation from the Boston District Office of the SEC.

TheStreet.com (http://www.thestreet.com/stocks/biotech/10220831.html?cm_ven=YAHOO&cm_cat=FREE&cm_ite=NA)